{"schema_version":"secwatch.filing_event.v1","accession":"0001933414-23-000054","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.086519+00:00","generated_at":"2026-06-12T05:00:26.231436+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Mineralys Therapeutics Q2 net loss $12.1M; cash $282.8M; Advance-HTN enrollment on track","bullets":["Net loss of $12.1M for Q2 2023 vs $6.5M in Q2 2022, driven by increased R&D and G&A spend.","Cash, equivalents and investments $282.8M as of June 30, 2023, up from $110.1M at Dec 31, 2022.","R&D expenses $11.9M vs $5.6M YoY, reflecting initiation of lorundrostat pivotal program.","Advance-HTN Phase 2 trial enrollment ongoing; topline data expected 1H 2024.","Phase 3 Launch-HTN trial and Phase 2 CKD trial both expected to start in 2H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001933414-23-000054","json":"https://secwatch.observer/filing/0001933414-23-000054.json","markdown":"https://secwatch.observer/filing/0001933414-23-000054.md","text":"https://secwatch.observer/filing/0001933414-23-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000193341423000054/0001933414-23-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000193341423000054/mlys-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T05:00:26.231436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"42be0d5c24019259e4c80c4e7197f3764c135372","claim":"Mineralys Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $12.1 million for the quarter ended June 30, 2023.","evidence_excerpt":"On August 7, 2023, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1933414/000193341423000054/0001933414-23-000054-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss was $12.1 million for the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}